Navigation Links
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
Date:6/26/2012

HOUSTON and NES-ZIONA, Israel, June 26, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today reported that researchers at ENDO 2012 presented data from the company's Phase II trial of its long acting human growth hormone, hGH-CTP, in growth hormone deficient adults.  The data, which were previously reported by the company, confirm that hGH-CTP has the potential to be administered once weekly to adults with growth hormone deficiency and that it appears to be safe and well tolerated.  The hGH-CTP data were discussed in an oral presentation at ENDO 2012, the 94th Annual Meeting and Expo of the Endocrine Society, which is being held in Houston Texas June 23-26, 2012.

"ENDO 2012 represents a great opportunity to share the encouraging data we have reported from our completed Phase II trial of hGH-CTP with leading endocrinologists from North America and around the world," noted Dr. Abraham Havron, CEO of PROLOR Biotech.  "These data further confirm the potential of our long acting version of human growth hormone to be administered once-weekly, in contrast to the daily injections currently required.  We believe that informing the broader endocrinology community about our progress with hGH-CTP is timely as we continue to enroll subjects in our Phase II trial in growth hormone deficient children and prepare to initiate a Phase III trial in growth hormone deficient adults, expected later this year."

The data presented at ENDO 2012 included results from the main component of the Phase II trial, which administered hGH-CTP to growth hormone deficient adults for four weeks, as well as top-line results from a four-month treatment extension study of hGH-CTP in a similar population.  As reported last month, these data reaffirm the company's prior Phase II findings showing that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
4. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
5. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
8. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
9. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
10. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
11. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 20, 2014 MediVet America ... a groundbreaking surgery at the specialized Wolvega Horse Clinic. ... digital flexor tendon was ruptured 90% and her deep ... is a death sentence for a horse. , The ... cell treatments . This revolutionary regenerative option for ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Nanotechnology and its potential to revolutionize the ... government agencies, multinational corporations and small start-ups. The ... government funded research projects largely due to the ... capital investments. Government budgets earmarked for this evolving ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... Aug. 30, 2011 Farmers in North Carolina will ... a partnership by Perdue AgriBusiness and Winston-Salem-based Technology Crops ... the crop looks identical to canola, but the oil ... applications, especially industrial uses.  Grown in trials in North ...
... Aug. 30, 2011 Amnis Corporation, a manufacturer of advanced ... acquired by EMD Millipore, the Life Science division of Merck ... and closing is expected to take place in the fourth ... disclosed. Amnis generated sales of USD 14 ...
... SANTA CLARA, Calif., Aug. 30, 2011 ProteinSimple today introduced ... Simple Western.  The Simple Western is a complete reinvention of ... protein research.  For the first time in 30 years, researchers ... analysis. The Western Blot was invented in ...
Cached Biology Technology:Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 2Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 3Perdue AgriBusiness and TCI Collaborate to Bring Profitable New Crop to North Carolina 4Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3ProteinSimple Reinvents the Western Blot 2
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... Va.Sept. 18, 2014Many Americans across racial and ethnic ... greatest impact on their day-to-day life, more so ... hearing and speech (57% of African-Americans, 49% of ... Hispanics). When asked which disease or ailment is ... ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2
... who can,t tolerate the side effects of cholesterol-lowering drugs ... study by researchers from the Intermountain Heart Institute at ... found that pitavastatin, a newer cholesterol-lowering drug, may reduce ... in up to 68 percent of patients with high ...
... amount of nitrogen into urban watersheds, diminishing both ... many studies documenting the impacts of nitrogen on ... of leaky sewer systemsuntil now., Aging sewer systems ... urban watersheds, diminishing both the quality of water ...
... journals will join John Wiley & Sons, Inc., a ... technical, medical, and scholarly research; professional development; and education, ... Wiley from other publishers or self-publication, and 14 new ... joining Wiley represent relationships with over 30 societies and ...
Cached Biology News:Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Pittsburgh's leaky faucet: How aging sewers are impacting urban watersheds 266 titles join Wiley's journal portfolio in 2013 2
... This book is unique in that ... techniques currently used in the diagnosis ... virus-specific antibodies and clinical virus isolates. ... blotting and hybridization procedures, PCR for ...
...
... PCR Purification Kits provide rapid and efficient ... PCR products, and salts from PCR products ... provides two Binding Buffer options for ... can be performed in either single column ...
... TOPO PCR Cloning Kit offers the ... (>=95%) cloning of blunt-end PCR products ... kit includes the linearized and topoisomerase ... bench-top ligations without ligase (1). The ...
Biology Products: